Confirmed Speakers Joining Us in 2022:
Mira Chaurushiya, Partner, 5AM Ventures
Marianne De Backer, PhD, MBA, EVP Global Head, Strategy & Business Development, Bayer
Janeen Doyle, VP, Head of Research & Early Dev Alliance Management, Bristol-Myers Squibb
Rusty Gage, President, Salk Institute
Carol Gallagher, Pharm.D., Venture Partner, NEA
Kevin Grimes, Professor of Chemical and Systems Biology; Co-director of the SPARK Program at Stanford University School of Medicine
Jason Hafler, Managing Director, Sanofi Ventures
Richard Heyman, Ph.D., Venture Partner, Arch Ventures; Founder and Executive Chairman of the Board, Metacrine Inc.
Mike Jung, Distinguished Professor of Chemistry, UCLA
Chau Khuong, Private Equity Partner, OrbiMed Advisors
Scott Lippman, Director, Moores Cancer Center, UC San Diego Health
Stefan Luzi, Partner, Gilde Healthcare
Shyam Masrani, Principal, Medicxi
Carole Nuechterlein, Head, Roche Venture Fund
Scott Platshon, Partner, EcoR1
Camille Samuels, Partner, Venrock
Avi Spier, PhD., Executive Director, Search & Evaluation, NIBR BD&L, Novartis Institutes for BioMedical Research
Jay Stamatis, Vice President, Head of Business Development and Acquisitions, AbbVie
Alex Szidon, Vice President and Head of Business Development, gRED, Genentech
Matt Trembley, Chief Operating Officer, Scripps Research
Jeffrey Warmke, Ph.D, Senior Vice President, Search and Evaluation & Alliance Management, Global Business Development, Daiichi Sankyo
2021 Past Conference Speakers:
Kate Bingham, Managing Director, SV Health Investors | Former Chair, UK Vaccine Taskforce (Until January 2021)
John Reed, Executive Vice President, Global Head of Research & Development, Sanofi
Moncef Slaoui, Partner, Medicxi, Former Scientific Head of Operation Warp Speed
Devang Bhuva, Senior Vice President, Corporate Development, Gilead Sciences
Marianne De Backer, PhD, MBA, EVP Global Head, Strategy & Business Development, Bayer
Francesco De Rubertus, Co-Founder and Partner, Medicxi
Jessica Droge, Vice President of Business Development, Amgen
Simone Fishburn, Ph.D., Vice President and Editor in Chief, BioCentury
Carol Gallagher, Pharm. D., Venture Partner, NEA
George Golumbeski, Independent Biotechnology Executive
Henry Gosebruch, Executive Vice President, Chief Strategy Officer, Abbvie
Jason Hafler, Managing Director, Sanofi Ventures
Reza Halse, President, Merck Research Labs Ventures Fund
Faheem Hasnain, Executive Advisor, Vertex Ventures
Richard Heyman, Ph.D., Venture Partner, Arch Ventures; Founder and Executive Chairman of the Board, Metacrine Inc.
Nina Kjellson, General Partner/West Coast, Canaan
Jim Krenn, Partner, Morrison & Foerster, LLP
Angele Maki, Ph.D., Vice President of Emerging Technology & Innovation, Eli Lilly
Oleg Nodelman, Founder and Managing Director, EcoR1 Capital Fund
Carole Nuechterlein, Head, Roche Venture Fund
Merdad Parsay, Chief Medical Officer, Gilead Sciences
Heather Preston, Managing Partner, Pivotal
Kyle Rasbach, Managing Partner, Pappas Ventures
Terry Rosen, Chief Executive Officer, Arcus
Camille Samuels, Partner, Venrock
Ioannis Sapountzis, Ph.D, Corporate Senior Vice President, Business Development, Boehringer Ingelheim Pharmaceuticals, Inc.
Uwe Schoenbeck, Ph.D, Senior Vice President and Chief Scientific Officer, Emerging Science and Innovation (ES&I), Pfizer Worldwide Research, Development, and Medical
Andrew Schwab, Managing Partner, 5am Ventures
Armen Shanafelt, Ph.D., General Partner, Lilly Ventures
Nigel Sheail, Global Head, Mergers & Acquisitions and Business Development & Licensing, Novartis
Kumar Srinivasan, Vice President, Global Head of Business Development & Licensing, Biopharmaceuticals R&D, AstraZeneca
Alex Szidon, Vice President and Head of Business Development, gRED, Genentech
Ben Thorner, SVP and Head of BD&L, Merck
Arda Ural, Americas Life Science & Healthcare Markets Leader, Ernst & Young
Jeffrey Warmke, Ph.D, Senior Vice President, Search and Evaluation & Alliance Management, Global Business Development, Daiichi Sankyo